ISP OR 15th HTA Roundtable
Health Technology Assessment in Asia
Wednesday, 5 September 2012, Grand Hyatt Taipei, Residence 2 (Lobby Level), Taipei

Organized by
HTAnetAsia (AsiaNetHTA) of ISPOR Asia Consortium

Summary

Moderators:
Jie Chen, PhD, 2012-2014 Chair, ISPOR Asia Consortium HTA Agencies Committee
Yen-Huei (Tony) Tarn, MS, PhD, 2012-2014 Chair-Elect, ISPOR Asia Consortium Executive Committee

Attendees:
Special Guest: Sir Andrew Dillon
Participants from Asia: Alima Almadiyeva, Kenneth Hartigan-Go, Takashi Fukuda, Alexander Kostyuk, Shanlian Hu, Seung-Min Lee, Kejun Liu, Mi-hai Park, Raoh-Fang Pwu, Mao-Ting Sheen, Haiying Wang, Bong-Min Yang, Xiaojuan Yang, Mi-Young You, Faridah Aryani Md. Yusof
ISPOR Staff: Zandra Yin, Nancy Sun, Robert Selby

Objective:
The purpose of this roundtable was to provide a platform for information sharing and dialogue between HTA assessors and health care decision-makers from countries in Asia and to explore the possibility of close collaboration on further HTA initiatives in the region.

Presentations:
- NICE & HTA: Valuing New Health Technologies: Sir Andrew Dillon presented an overview of how new health technologies are valued at NICE. Sir Andrew provided a background on key decision criteria including a Cost per QALY acceptability curve, and “special considerations” for orphan drugs or higher cost drugs. Future directions for NICE were also highlighted, e.g. a new scheme in 2014 which may allow for more flexibility in price negotiation and cost considerations to address Value-Based Pricing.
- HIRA & HTA: Director Mi-Young You presented the Drug Pricing and Reimbursement System for South Korea, which included an overview of the National Health Insurance Program, the process for drug listing and reimbursement, and recent achievements and current issues. The Ministry of Health announced reform of the pharmaceutical pricing process and preparation of a support plan to stimulate innovation, which will require companies to create a long-term R&D roadmap. South Korea adopted guidelines for indirect treatment comparisons, and revised their PE guidelines. Also ICERs will be considered flexibly for orphan drugs or end of life treatments.
- CDE & HTA: Dr. Raoh-Fang Pwu gave an overview of HTA in Taiwan from the perspective of the Center for Drug Evaluation (CDE). The Drug listing review process in Taiwan was presented, which highlighted its rapid turnaround—approximately 42 days. Currently cost-effective analysis (CEA) is still under development, as well as HTA for medical devices, and NHI has suggested that database analysis may play a future role in the process.
- WHO & HTA: Professor Jie Chen outlined the World Health Organization’s HTA training projects in West Pacific region and introduced recent HTA training activities in China. WHO recently has provided $90,000 to fund a databank which will provide a foundation for future HTA development in China.
- ISPOR & HTA: Zandra Yin demonstrated ISPOR’s new decision maker toolkit, a web-based checklist. Questions are precluded by targeted explanations to assist the user in making rational and information-optimized decisions. The toolkit features a login portal for security and user-friendly dashboard.
- Overview: HTA Fast Growing in Asia: Dr. Tony Tarn provided an informative overview of different HTA systems around the world, including the UK, Taiwan and South Korea. The structures of the decision making bodies, as well as the decision making process itself were discussed.
Presentations will be disseminated among the HTA Roundtable presentations along with the HTA Roundtable presentations. (*Suggested after the Roundtable)

It was suggested that an article on HTA in Asia be developed for a yearly HTA roundtable/forum that would provide a regular platform for exchange in the region. It was discussed that the next possible roundtable should take place in the Philippines in May 2013.

A two-three day training aimed at local capacity building may follow the HTA roundtable/forum, which may be co-organized by the ISPOR Philippines Chapter. The training may be held in Asian Institute of Management. (*Suggested after the Roundtable)

It was suggested that HTA training materials be developed to meet the needs of the Asia region. In addition to introductions of HTA basic principles, a training course on negotiations (communication) between HTA agencies, government decision-making bodies and industry was also suggested.

It was suggested that a white paper be drafted that highlights the 15 principles of HTA assessment based upon Professor Mike Drummond et al paper *Key Principles for the Improved Conduct of Health Technology Assessments for Resource Allocation Decisions* that could be used as a template for regional localization. This document could be adapted by local researchers and presented to the relevant decision-making body in each country. It was decided that based on these 15 principles Dr. Tarn develop a survey questionnaire for as many countries (in Asia) as possible to respond and the survey result be presented at the next HTA roundtable.

It was suggested that an article on HTA in Asia be developed for ViHRI Volume 3 Issue 1 focusing on Asia, which would be published in May 2014. This article would consist of the 5th AP Conference 1st plenary session presentations along with HTA Roundtable presentations. (*Suggested after the Roundtable).

Presentations will be disseminated among the HTA Roundtable delegates for reference.